A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of 3K3A-APC, a Recombinant Variant of Human Activated Protein C (APC), in Healthy Adult Volunteers

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of 3K3A-APC, a Recombinant Variant of Human Activated Protein C (APC), in Healthy Adult Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2014

At a glance

  • Drugs 3K3A APC (Primary)
  • Indications Embolism and thrombosis; Stroke
  • Focus Adverse reactions
  • Sponsors ZZ Biotech
  • Most Recent Events

    • 13 Feb 2013 Results will be made available in 2013, according to ZZ Biotech.
    • 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top